A prospective, open label phase 2 clinical trial assessing safety, complications and feasibility of radical prostatectomy (RARP) plus local stereotactic body radiotherapy (SBRT) to bone metastases in combination with short-term medical castration to a select population of prostate cancer patients with oligometastatic disease.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
20
Herlev and Gentofte Hospital
Herlev, Denmark
RECRUITINGProportion of men with Grade ≥ 3 adverse events the first year
Proportion of men with Grade ≥ 3 adverse events the first year
Time frame: 1 year
Proportion of men achieving prostatic specific antigen (PSA) < 0.1 ng/ml
Proportion of men achieving prostatic specific antigen (PSA) \< 0.1 ng/ml
Time frame: 1 year
Feasibility of radical prostatectomy in the oligometastatic setting
Feasibility of radical prostatectomy in the oligometastatic setting measured as number of patients who successfully undergo radical prostatectomy with pelvic lymphnode disection and 30 days (post-operative) morbidity according to the Clavian Dindo Classification.
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.